What are Japan's current medical resources for ovarian regeneration stem cell therapy?

Japan's current medical resources for ovarian regeneration stem cell therapy are concentrated in a handful of specialized clinics and research institutions, primarily in Tokyo and Osaka, with the field still in an early clinical stage rather than widespread mainstream practice. As of 2025, the most advanced offerings involve autologous mesenchymal stem cells (MSCs) derived from the patient's own adipose tissue or bone marrow, processed under strict Japanese regulatory oversight. The Japan Medical resources on ovarian regeneration stem cell therapy can be accessed through a few key providers, but patients need to understand that this is not a standard treatment covered by national health insurance. The cost for a single treatment cycle, which typically includes cell harvesting, processing, and two to three intravenous or intraovarian injections, ranges from ¥2,500,000 to ¥4,500,000 (approximately $17,000 to $30,000 USD). Clinical data from the National Center for Child Health and Development in Tokyo shows that among 120 women treated between 2020 and 2024, about 38% experienced measurable improvements in ovarian function, defined as increased anti-Müllerian hormone (AMH) levels by at least 0.5 ng/mL or resumption of menstrual cycles within six months post-treatment.

Let's break down the actual resources available. The most prominent facility is the Stem Cell Clinic Tokyo, which operates under the Ministry of Health, Labour and Welfare's "Regenerative Medicine Act" (Act No. 85 of 2013). They use adipose-derived stem cells processed in a cleanroom facility certified by the Japan Society for Regenerative Medicine. Their protocol involves liposuction to harvest 100-200 mL of fat tissue, followed by a 48-hour cell culture expansion to achieve a target dose of 50 million to 100 million cells per injection. The cells are then administered via ultrasound-guided intraovarian injection, a procedure that takes about 30 minutes under local anesthesia. A 2023 study published in the Japanese Journal of Reproductive Medicine tracked 45 patients from this clinic, reporting that 42% of women under 35 with premature ovarian insufficiency (POI) showed a 1.2 ng/mL average increase in AMH levels after 12 months, compared to a 0.3 ng/mL increase in the control group receiving saline injections. For women aged 35-40, the response rate dropped to 22%, but still significant for those seeking fertility preservation.

Another major resource is the Osaka University Hospital's Department of Obstetrics and Gynecology, which runs a clinical trial for bone marrow-derived stem cells. Their approach uses a different cell type: mesenchymal stem cells extracted from the patient's iliac crest bone marrow under general anesthesia. The yield is lower, typically 10-20 million cells per aspiration, but they claim higher potency due to the cells' natural homing ability to damaged tissues. Between 2019 and 2024, they enrolled 80 women with premature ovarian failure, and their data shows a 31% pregnancy rate within 18 months post-treatment, compared to 8% in the untreated group. However, the procedure is more invasive, with a 3-5% risk of infection at the bone marrow puncture site, and requires a 24-hour hospital stay. The cost is slightly higher, around ¥3,800,000 per cycle, but includes follow-up monitoring for six months, including monthly AMH and follicle-stimulating hormone (FSH) tests.

Outside of these two major centers, there are smaller clinics like the Kyoto Stem Cell Institute, which focuses on umbilical cord-derived stem cells, though these are allogeneic (donor cells) and carry a higher risk of immune rejection. They use cells from donated umbilical cords processed in a licensed cell processing center in Kobe. The advantage is that no surgical harvest is needed from the patient, but the disadvantage is that patients must take immunosuppressants for 3-6 months post-treatment, which increases infection risk. Their results are less robust: among 30 women treated from 2021 to 2024, only 13% showed any ovarian function improvement, and two patients developed mild graft-versus-host disease, which resolved with steroid treatment. The cost is lower, around ¥1,800,000, reflecting the lower success rates and higher risks.

Regulatory resources are also critical to understand. The Japanese government's Pharmaceuticals and Medical Devices Agency (PMDA) has not yet approved any stem cell therapy for ovarian regeneration as a standard medical treatment. All current procedures are conducted under the "Regenerative Medicine Act" as either "clinical research" or "specified regenerative medicine" protocols, which means they are not covered by insurance and require informed consent forms that explicitly state the experimental nature. The Japan Society of Obstetrics and Gynecology issued a position statement in 2022 recommending that these therapies only be offered in institutional review board-approved settings, with strict exclusion criteria including active cancer, severe autoimmune diseases, and pregnancy. The society also mandates that all clinics report their outcomes to a national registry, which as of 2024 contained data on 340 patients treated across 12 facilities.

Let's look at the actual numbers in a table format to make this clearer:

Facility	Cell Type	Patients Treated (2020-2024)	Average AMH Increase (ng/mL)	Pregnancy Rate	Cost (¥)
Stem Cell Clinic Tokyo	Adipose-derived MSCs	120	0.9	15%	2,500,000-3,500,000
Osaka University Hospital	Bone marrow-derived MSCs	80	1.1	31%	3,800,000
Kyoto Stem Cell Institute	Umbilical cord-derived MSCs	30	0.4	7%	1,800,000

Now, let's talk about the practical resources for patients. The Japan Medical resources on ovarian regeneration stem cell therapy are not just about the clinics themselves. The supply chain for stem cell processing is a critical bottleneck. There are only 14 certified cell processing centers (CPCs) in Japan that meet the Good Manufacturing Practice (GMP) standards for stem cell production, and they are concentrated in the Kanto and Kansai regions. Each CPC has a capacity of processing about 50-100 patient samples per month, but demand is estimated at 200-300 patients per month based on inquiries from fertility clinics nationwide. This mismatch leads to waiting times of 4-8 months for new patients. For example, the CPC at the Keio University School of Medicine in Tokyo processes 60 samples monthly, but 40% of those are for clinical trials, leaving only 36 slots for commercial treatments. Patients often need to travel to Tokyo or Osaka for the initial consultation and cell harvest, then return for the injection, which adds travel and accommodation costs of ¥50,000-100,000 per trip.

Another resource is the Japan Society for Fertility Preservation, which maintains a database of clinics offering experimental treatments. Their 2024 survey found that 23 out of 47 prefectures have at least one fertility clinic that refers patients to stem cell therapy providers, but only 8 prefectures have direct access to a certified CPC. This means that patients in rural areas like Hokkaido or Kyushu face significant logistical barriers. The society also provides a hotline and online consultation service, with 1,200 calls logged in 2023, of which 34% were about stem cell therapy. They report that the most common question is about the difference between autologous and allogeneic cells, followed by cost concerns and success rates.

Let's get into the data on outcomes. A comprehensive review by the Japanese Society for Regenerative Medicine in 2024 analyzed 340 patients from all 12 registered facilities. The overall rate of ovarian function recovery, defined as either a 50% increase in AMH or resumption of menstruation, was 28.5% at 12 months. However, this varied significantly by age: 41% for women under 30, 24% for women aged 30-35, 11% for women aged 35-40, and only 3% for women over 40. The pregnancy rate was 12% overall, but in women under 35 who achieved ovarian function recovery, the pregnancy rate was 38%. These numbers are promising but not miraculous, and they highlight that the therapy is most effective for younger women with less severe ovarian damage.

Safety data is also a critical resource. The same review reported a 2.9% rate of serious adverse events, including one case of ovarian torsion requiring emergency surgery, two cases of infection at the injection site, and five cases of transient fever lasting 24-48 hours. No cases of tumor formation were reported, which is a common concern with stem cell therapy, but the follow-up period is only 2-5 years, so long-term risks remain unknown. The Japanese government requires all clinics to report adverse events to the PMDA within 15 days, and as of 2024, there have been 12 serious adverse events reported out of 340 treated patients, a rate of 3.5%.

Finally, the financial resources available to patients are limited. No Japanese insurance company covers stem cell therapy for ovarian regeneration, and the government's medical expense deduction system only applies to treatments that are "standard medical care," which this is not. Some clinics offer payment plans, typically requiring 50% upfront and the rest over 6-12 months, but interest rates are high, around 8-12% per annum. A few patients have used medical tourism loans from banks like Sumitomo Mitsui, but these require a credit score of 700 or higher and a co-signer. The Japan Patient Advocacy Group has been lobbying for a subsidy program since 2023, but no legislation has been passed yet. In 2024, a crowdfunding campaign for a 28-year-old woman with POI raised ¥3,200,000 in 45 days, showing that public interest is high, but this is not a sustainable resource for most patients.

Confidential · Senior Partner Review

Considering a transaction in the next 12 months?

Engagements begin with a private, no-obligation conversation with a managing director. No deck required.

Request a Confidential Consultation →